2-chloro-3,6-dimethylquinoxaline

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-chloro-3,6-dimethylquinoxaline
• 英文别名: 2-chloro-3,6-dimethyl-quinoxaline；2-Chlor-3,6-dimethyl-chinoxalin；2-Chloro-3,6-dimethylquinoxaline
• 化学式: C₁₀H₉ClN₂
• 分子量: 192.648
• InChiKey: LKNVXTRRGQNDLD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-chloro-3,6-dimethylquinoxaline 在 palladium on activated charcoal 、 sodium acetate 、 溶剂黄146 作用下， 生成 2,7-dimethyl -1,2,3,4-tetrahydroquinoxaline
  参考文献：
  名称：

  Quinoxaline Studies. IV. The Preparation of dl-2,6-Dimethyl-1,2,3,4-tetrahydroquinoxaline and dl-2,7-Dimethyl-1,2,3,4-tetrahydroquinoxaline

  摘要：

  DOI：

  10.1021/ja01133a520
• 作为产物：
  描述：

  丙酮酸甲酯 、 3,4-二氨基甲苯 在 苯膦酰二氯 作用下， 以 甲醇 为溶剂， 反应 8.0h， 生成 2-chloro-3,7-dimethylquinoxaline 、 2-chloro-3,6-dimethylquinoxaline
  参考文献：
  名称：

  [EN] TRIAZOLOPYRAZINE DERIVATIVES AND THEIR USE FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS
  [FR] DÉRIVÉS DE TRIAZOLOPYRAZINE ET LEUR UTILISATION POUR LE TRAITEMENT DE TROUBLES NEUROLOGIQUES ET PSYCHIATRIQUES

  摘要：

  本发明涉及式(I)的三唑吡嗪化合物。该发明的不同方面涉及包含所述化合物的药物组合物以及将该化合物用作治疗神经系统和精神疾病的治疗剂的用途。

  公开号：

  WO2013034755A1

文献信息

• 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES
  申请人：Andrés-Gil José Ignacio

  公开号：US20140147386A1

  公开（公告）日：2014-05-29

  The present invention relates to novel 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]-quinoxaline derivatives as inhibitors of phosphodiesterase 2 (PDE2) and to a lesser extent of phosphodiesterase 10 (PDE10) or as inhibitors of both, phosphodiesterases 2 and 10. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which PDE2 is involved, or disorders in which both PDE2 and PDE 10 are involved, such as neurological and psychiatric disorders, and endocrinological or metabolic diseases. The present invention also relates to radiolabelled compounds which may be useful for imaging and quantifying the PDE2 enzyme in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue, cells or a host, in vitro or in vivo and to precursors of said compounds.
• [EN] TRIAZOLOPYRAZINE DERIVATIVES AND THEIR USE FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS<br/>[FR] DÉRIVÉS DE TRIAZOLOPYRAZINE ET LEUR UTILISATION POUR LE TRAITEMENT DE TROUBLES NEUROLOGIQUES ET PSYCHIATRIQUES
  申请人：LUNDBECK & CO AS H

  公开号：WO2013034755A1

  公开（公告）日：2013-03-14

  The present invention is directed to triazolopyrazine compounds of Formula (I). Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds as therapeutic agents treating neurological and psychiatric disorders.

  本发明涉及式(I)的三唑吡嗪化合物。该发明的不同方面涉及包含所述化合物的药物组合物以及将该化合物用作治疗神经系统和精神疾病的治疗剂的用途。
• Quinoxaline Studies. IV. The Preparation of dl-2,6-Dimethyl-1,2,3,4-tetrahydroquinoxaline and dl-2,7-Dimethyl-1,2,3,4-tetrahydroquinoxaline
  作者：Morton Munk、Harry P. Schultz

  DOI：10.1021/ja01133a520

  日期：1952.7